脑胶质瘤显微手术切除后植入缓释化疗药物联合增敏放疗的临床疗效  

Clinical Observation of Delayed Release Chemotherapy Combined with Sensitizing Radiotherapy for Glioma after Microsurgery Resection

作　　者：刘正清[1] 买买提艾力.吐尔逊 陈勇[1] 颜云峰[1] 米尔卡斯木.吾布力 玉山江.莫合太尔 买买提吐尔洪.依明 罗琴[2] 

机构地区：[1]新疆喀什地区第一人民医院,844000 [2]新疆生产建设兵团第三师医院,844000

出　　处：《实用癌症杂志》2018年第2期207-210,共4页The Practical Journal of Cancer

摘　　要：目的探究脑胶质瘤显微手术切除后植入缓释化疗药物联合增敏放疗的临床疗效。方法选择80例脑胶质瘤患者。根据患者病情、经济状况并结合患者自主意愿将患者分为观察组(43例)和对照组(37例)。两组患者手术方法相同,均给予常规治疗;在此基础上对照组患者给予全身化疗,术后两周给予普通放射、X刀、γ刀治疗;观察组患者在肿瘤切除后,在瘤床上植入缓释化疗粒子并配合全脑增敏放疗。随访6个月~3年,比较两组患者的肿瘤复发率、生存率、不良反应发生情况及生存质量。结果术后6个月及1年随访期间内,两组患者的肿瘤复发率比较,差异无统计学意义(P>0.05),术后2~3年,观察组患者的肿瘤复发率显著低于对照组(P<0.05)。术后1、2、3年,观察组患者生存率显著高于对照组患者(P<0.05);两组患者不良反应发生情况比较,差异无统计学意义(P>0.05);术后1个月两组患者KPS评分与手术前相比均显著增加,且观察组患者显著高于对照组患者(P<0.05)。结论脑胶质瘤显微手术切除后植入缓释化疗药物联合增敏放疗,临床效果较好,无明显的不良反应,在大样本量深入研究确认其疗效后,可扩大临床实践。Objective To explore the clinical efficacy of implantation of sustained release chemotherapy drug combined with sensitization radiotherapy for glioma after microsurgery resection. Methods 80 patients with brain glioma were selected,and according to the patientg condition, economic condition and inclination, they were divided into the observation group （43 cases） and the control group （37 cases）. The same operation method was used in the 2 groups, and all patients were given routine treat- ment. On this basis, the control group were treated with systemic chemotherapy, and given general radiotherapy, X knife, -/ knife treatment 2 weeks after operation. After resection operation,the observation group were implanted sustained release chemotherapy medicine in tumor bed and combined with whole brain sensitization radiotherapy. And the observation group were followed up for 6 36 months. Tumor recurrence rate, survival rate, incidence of adverse reactions and quality of life were compared between the 2 groups. Results After operation follow-up period of 6 months and 1 year,compare the rate of tumor recurrence in the 2 groups, there was no statistically significant difference （ P 〉 0.05 ）. After operation 2 - 3 years, the observation group with tumor recur- rence rate was significantly lower than the control group （P 〈 0.05）. 1 year,2 years,and 3 years after operation,the survival rate of patients of the observation group were significantly higher than the control group （ P 〈 0.05 ） ; the incidence of adverse reactions between the 2 groups had no statistically significant difference（P 〉 0.05）. 1 month after operation,the KPS score in the 2 groups significantly increased compared with before operation, and the observation group were significantly higher than the control group （P 〈 0.05 ）. Conclusion After glioma microsurgery resection, implanting sustained release chemotherapy medicine combined with sensitization radiotherapy have good clinical effect, and no obvious adverse reaction.

关 键 词：脑胶质瘤 显微手术切除 缓释化疗药物植入 增敏放疗 

分 类 号：R730.264[医药卫生—肿瘤]